Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600X PIK3CA H1047X |
Therapy | Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus |
Indication/Tumor Type | ovarian carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600X PIK3CA H1047X | ovarian carcinoma | predicted - sensitive | Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus | Case Reports/Case Series | Actionable | In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929). | 21216929 |
PubMed Id | Reference Title | Details |
---|---|---|
(21216929) | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. | Full reference... |